1445590-35-1

Basic information

• Product Name: (R)-2-bromo-N-(1-hydroxypropan-2-yl)-N-(4-methoxybenzyl)acetamide
• Synonyms: (R)-2-bromo-N-(1-hydroxypropan-2-yl)-N-(4-methoxybenzyl)acetamide
• CAS NO: 1445590-35-1
• Molecular Weight: 316.195
• Mol File: 1445590-35-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (R)-2-bromo-N-(1-hydroxypropan-2-yl)-N-(4-methoxybenzyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-bromo-N-(1-hydroxypropan-2-yl)-N-(4-methoxybenzyl)acetamide(1445590-35-1)
• EPA Substance Registry System: (R)-2-bromo-N-(1-hydroxypropan-2-yl)-N-(4-methoxybenzyl)acetamide(1445590-35-1)

Safety Data

• Hazardous Substances Data: 1445590-35-1(Hazardous Substances Data)

Upstream product

• 598-21-0 2-Bromoacetyl bromide 
• 570398-17-3 (R)-2-((4-methoxybenzyl)amino)propan-1-ol 
• 123-11-5 4-methoxy-benzaldehyde 
• 86941-39-1 (R,E)-2-((4-methoxybenzylidene)amino)propan-1-ol 

Downstream Products

• 1445589-63-8 methyl ((S)-3-hydroxy-1-((S)-2-(5-(4-(2-((1S,2S)-2-((R)-3-methylmorpholine-4-carbonyl)cyclopentyl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-1-oxopropan-2-yl)carbamate 
• 1445590-34-0 ((1,2-trans)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclobutyl)((R)-3-methylmorpholino)methanone 
• 1445590-40-8 ((R)-3-methylmorpholino)((1,2-trans)-2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)cyclobutyl)methanone 
• 570398-22-0 (R)-4-(4-methoxybenzyl)-5-methylmorpholin-3-one 
• 954133-47-2 (R)-4-(4-methoxybenzyl)-3-methylmorpholine 
• 74572-04-6 (3R)-3-methylmorpholine 
• 1445591-17-2 (1R,2R)-2-((R)-3-methylmorpholine-4-carbonyl)cyclohexanecarboxylic acid 
• 1445590-45-3 ((1R,2R)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclohexyl)((R)-3-methylmorpholino)methanone 
• 1445590-70-4 ((1S,2S)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclopentyl)((R)-3-methylmorpholino)methanone 
• 1445590-41-9 ((1R,2R)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclopentyl)((R)-3-methylmorpholino)methanone 
• 1445590-77-1 ((R)-3-methylmorpholino)((1R,2R)-2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)cyclopentyl)methanone 
• 1445590-83-9 ((7R,8R)-8-(5-(4-bromophenyl)-1H-imidazol-2-yl)-1,4-dithiaspiro[4.4]nonan-7-yl)((R)-3-methylmorpholino)methanone 
• 1445589-06-9 (S)-tert-butyl 2-(5-(4-(2-((1S,2S)-2-((R)-3-methylmorpholine-4-carbonyl)cyclopentyl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1445597-10-3 methyl ((S)-1-((2S,4S)-4-methoxy-2-(5-(4-(2-((1R,2R)-2-((R)-3-methylmorpholine-4-carbonyl)cyclopentyl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate 

Relevant articles and documents

NOVEL HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein Rings A and A' are independently 5-membered optionally substituted aromatic heterocycles; Q is C(=O)NR1R1' or formula U is C(R4)2, O, S, S(=O)2, C(R4)2C(R4)2, CH2O, OCH2, CH2S, SCH2, CH2S(=O)2, S(=O)CH2 or C=C(Ru )2; X is CH2, CHR12, CR12R12, O, S, S(=O)2 or NRx; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.